On Visit To Japan, Sanofi’s Viehbacher Weighs In On Innovation Models, Clinical Trial Transparency
This article was originally published in PharmAsia News
Increased funding and public-private interaction in a new research “control tower” would be welcomed by industry in Japan, Viehbacher said. But the CEO told PharmAsia News that he opposes expanded regulatory oversight on clinical trial transparency.
You may also be interested in...
With a new budget of €3.4 billion over the next seven years, Europe’s public-private partnership in health aims to tackle difficult-to-treat neurodegenerative diseases and new antibiotics.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.